Log In
BCIQ
Print this Print this
 

Xelpros

  Manage Alerts
Collapse Summary General Information
Company Sun Pharma Advanced Research Company Ltd.
DescriptionFormulation of the glaucoma medication Latanoprost using novel Swollen Micelle Microemulsion (SMM) technology
Molecular Target Prostaglandin F (FP) receptor (PTGFR)
Mechanism of ActionProstaglandin F (FP) receptor agonist
Therapeutic Modality 
Latest Stage of DevelopmentRegistration
Standard IndicationGlaucoma
Indication DetailsTreat glaucoma
Regulatory Designation
PartnerSun Pharmaceutical Industries Ltd.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

$3.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/09/2015

Undisclosed

$3.0M

Undisclosed

Get a free BioCentury trial today